Greg Suvannovich predicts EyePoint's second phase three trial data will be available in October 2026.
“the second phase three set of data are expected in October. You know, if investors had completely written off this drug, instead of the stock being down 75%, it'd probably be down 90% or so. I think that is a reflection that some investors are still, potentially optimistic that the second trial, will work.”
→ Read the source episode
Our resolution criterion
disputableEyePoint announces second phase three trial results for their wet AMD treatment.
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.